Form 4: ClearPoint Neuro Director B. Kristine Johnson Granted 12,417 Restricted Stock Units

ClearPoint Neuro, Inc. Director B. Kristine Johnson was granted 12,417 restricted stock units, which will vest based on time or the company's 2026 annual meeting.

Summary

• B. Kristine Johnson, a Director of ClearPoint Neuro, Inc. (CLPT), reported the acquisition of restricted stock units.
• The transaction occurred on May 22, 2025, and involved the grant of 12,417 Restricted Stock Units (RSUs).
• Each RSU represents a contingent right to receive one share of ClearPoint Neuro, Inc. common stock.
• The RSUs were acquired at a price of $0, which is typical for equity grants.
• These restricted stock units are scheduled to vest on the earlier of (i) the first anniversary of the grant date (May 22, 2026), or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders.
• Following this transaction, B. Kristine Johnson beneficially owns 12,417 restricted stock units directly.

Sentiment

Score: 7

Explanation: The grant of restricted stock units to a director is a positive sign of aligning management and shareholder interests, though it is a routine compensation event and does not indicate extraordinary news.

Positives

• The grant of restricted stock units to a director aligns their interests with those of the shareholders, as the value of the compensation is tied to the company's stock performance.
• Equity compensation is a standard practice for attracting and retaining qualified board members.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future financial performance or strategic outlook, beyond the vesting schedule of the granted equity.

Management Comments

• The grant of 12,417 Restricted Stock Units to Director B. Kristine Johnson reflects the company's ongoing equity compensation practices for its board members.

Industry Context

The grant of restricted stock units to a director is a common and standard practice across various industries for compensating board members and aligning their long-term interests with the company's performance and shareholder value. This transaction is routine for publicly traded companies.

Comparison to Industry Standards

• Equity grants, such as Restricted Stock Units, are a widely accepted form of non-cash compensation for directors in public companies, consistent with corporate governance best practices.
• The vesting schedule, tied to either a time-based anniversary or the next annual meeting, is a typical structure for director equity awards, similar to practices observed in companies like Medtronic (MDT) or Stryker (SYK) within the medical technology sector, which often use similar mechanisms to incentivize long-term commitment.

Corporate Governance

Related Party Transactions

• The grant of 12,417 Restricted Stock Units by ClearPoint Neuro, Inc. to B. Kristine Johnson, a Director, constitutes a related party transaction as it involves compensation from the company to an insider.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's interests with shareholders, potentially leading to decisions that enhance long-term stock value.
• Employees: While not directly impacting employees, the compensation structure for directors can reflect the company's overall approach to incentivizing key personnel.

Next Steps

• The Restricted Stock Units will vest on the earlier of May 22, 2026, or the day immediately preceding the Company's 2026 annual meeting of stockholders, at which point they will convert into common stock.

Key Dates

Keywords

ClearPoint Neuro, CLPT, Restricted Stock Units, RSU, Director, Equity Grant, Insider Transaction, Form 4, Compensation